IRON — Disc Medicine, Inc. stock price, charts and financials

QT67Disc Medicine, Inc.

Disc Medicine, Inc. (NASDAQ: IRON) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
77.69
+0.25+0.32%
OverviewShort InterestFilings
IRONQT67Disc Medicine, Inc.·NASDAQ
77.69+0.32%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
GRAL+7.89%$74.96GPCR-0.78%$52.73KOD-2.25%$44.35IOVA+1.58%$6.44BEAM+0.04%$27.49ARQT+1.82%$25.75TARS+0.70%$65.25CLDX+2.40%$42.71
Snapshot
Index-P/E-EPS (ttm)-Insider Own28.45%Shs Outstand38.39MPerf Week0.57%
Market Cap2.97BForward P/E-EPS next Y-7.04Insider Trans-1.56%Shs Float27.61MPerf Month-1.90%
Enterprise Value2.94BPEG0.32EPS next Q-1.68Inst Own-Short Float26.41%Perf Quarter14.67%
Income-244.09MP/S0.00EPS this Y-Inst Trans-Short Ratio12.90Perf Half Y-1.14%
Sales0.00P/B4.65EPS next Y-6.51%ROA-33.45%Short Interest7.29MPerf YTD-2.48%
Book/sh-P/C-EPS next 5Y-ROE-37.17%52W High99.82 -22.17%Perf Year31.25%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-38.19%52W Low40.13 93.60%Perf 3Y55.10%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility3.57% 4.44%Perf 5Y90.27%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-66.16%Oper. Margin0.00%ATR (14)3.29Perf 10Y-
Dividend Ex-Date-Quick Ratio24.14Sales Y/Y TTM-Profit Margin0.00%RSI (14)54.99Recom1.91
Dividend Gr. 3/5Y-Current Ratio24.14EPS Q/Q2.53%SMA202.03%Beta0.95Target Price101.60
Payout0.00%Debt/Eq0.09Sales Q/Q-SMA505.42%Rel Volume0.55Prev Close77.44
Employees155LT Debt/Eq0.00EarningsNov 05SMA2003.66%Avg Volume560.68KPrice77.69
IPO DateAug 12, 2020Option/ShortYes / YesEPS/Sales Surpr.10.08% -Net Debt/EBITDA0.16Volume307,548Change0.32%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26ReiteratedMorgan StanleyOverweight$75 → $80
Feb-17-26ReiteratedMorgan StanleyOverweight$120 → $75
Feb-17-26ReiteratedStifel Nicolaus$125 → $110
Feb-17-26ReiteratedBMO CapitalOutperform$112 → $100
Feb-17-26ReiteratedCantor FitzgeraldOverweight$125
Feb-17-26ReiteratedWedbushOutperform$110 → $88
Jan-08-26ReiteratedMorgan StanleyOverweight$115 → $120
Dec-08-25ReiteratedRaymond JamesStrong Buy$108 → $117
Nov-10-25ReiteratedTruist SecuritiesBuy$114
Oct-17-25ReiteratedNational Bank$132 → $153
Latest News
Aug-08-26
Aug-08-2611:08AM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONnewsfilecorp.com
Aug-06-26
Aug-06-2606:30PM
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONprnewswire.com
06:21AM
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120Benzinga
Aug-04-26
Aug-04-2605:40PM
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rightsglobenewswire.com
Aug-02-26
Aug-02-2612:04PM
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONnewsfilecorp.com
Aug-01-26
Aug-01-2612:27PM
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONprnewswire.com
Jul-31-26
Jul-31-2604:22PM
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rightsglobenewswire.com
Jul-30-26
Jul-30-2610:36PM
ROSEN, A LONGSTANDING FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONnewsfilecorp.com
08:37AM
Disc Medicine Q2 EPS $(1.54) Beats $(1.77) EstimateBenzinga
08:30AM
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com
Jul-28-26
Jul-28-2607:01PM
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rightsglobenewswire.com
Jul-27-26
Jul-27-2603:58PM
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONprnewswire.com
Jul-24-26
Jul-24-2611:37AM
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONnewsfilecorp.com
Jul-22-26
Jul-22-2608:28PM
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rightsglobenewswire.com
Jul-21-26
Jul-21-2608:39PM
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONnewsfilecorp.com
Company

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000———
Cost of Goods Sold Incl. D&A
000———
Gross Profit
000———
Selling, General and Administrative Excl. Other653322———
Research and Development1719769———
Other Operating Expense
000———
Operating Income-236-130-91———
Interest Expense410———
Unusual Expense
——————
Non-Operating Income (Expense)282115———
Net Income Before Taxes-212-109-76———
Income Taxes
000———
Consolidated Net Income-212-109-76———
Net Income From Continuing Operations-212-109-76———
Net Income-212-109-76———
EPS (Recurring)-6.01-3.96-3.42———
EPS (Basic, Before Extraordinaries)-6.01-3.96-3.42———
EPS (Diluted)-6.01-3.96-3.42———
EBITDA-208-108-76———
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio
——————
Price To Sales Ratio
——————
Gross Margin
——————
Operating Margin
——————
Net Margin
——————
Shares Outstanding352822———
Market Capitalization2,7791,7751,271———
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$101.22$85.81$70.40$54.98$39.57● Close Price0.00M18.56M37.12M55.67M74.23MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Khara RahulChief Legal OfficerAug 06 '26Sale80.005,000400,00052,324Aug 07
Khara RahulChief Legal OfficerAug 06 '26Option Exercise14.695,00073,45057,324Aug 07
Quisel John DChief Executive OfficerJul 13 '26Option Exercise10.6833,000352,374259,064Jul 14
Quisel John DChief Executive OfficerJul 13 '26Sale74.9633,0002,473,780226,064Jul 14
Yu Jonathan Yen-WenChief Operating OfficerJul 07 '26Sale82.501008,25054,324Jul 09
Yu Jonathan Yen-WenChief Operating OfficerJul 07 '26Option Exercise13.501001,35054,424Jul 09
Khara RahulChief Legal OfficerJun 29 '26Option Exercise14.691,64924,22453,822Jun 30
Khara RahulChief Legal OfficerJun 29 '26Sale75.001,649123,67552,173Jun 30
Yu Jonathan Yen-WenChief Operating OfficerJun 26 '26Sale72.5030021,75054,324Jun 30
Yu Jonathan Yen-WenChief Operating OfficerJun 26 '26Option Exercise13.503004,05054,624Jun 30
Khara RahulChief Legal OfficerJun 26 '26Option Exercise14.6985112,50153,024Jun 30
Yu Jonathan Yen-WenChief Operating OfficerJun 22 '26Option Exercise13.509,700130,95064,024Jun 24
Yu Jonathan Yen-WenChief Operating OfficerJun 22 '26Sale72.669,700704,79554,324Jun 24
Khara RahulChief Legal OfficerJun 18 '26Sale70.227,500526,66052,173Jun 23
Khara RahulChief Legal OfficerJun 18 '26Option Exercise14.697,500110,17559,673Jun 23
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.